Targeted therapy for malignant glioma patients: lessons learned and the road ahead. - Wikidata - awgldk - TriplyDB

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

http://www.wikidata.org/entity/Q37533648

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells Astrocytes: biology and pathology Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma Lipid metabolism emerges as a promising target for malignant glioma therapy.Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways.AKT pathway genes define 5 prognostic subgroups in glioblastoma.ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain Molecular targeting of glioblastoma: Drug discovery and therapies Medical therapy of gliomas.Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines.The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance.Akt signaling is required for glioblastoma maintenance in vivo The challenges and the promise of molecular targeted therapy in malignant gliomas.Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells Glioblastoma multiforme: novel therapeutic approaches microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells Gab3 overexpression in human glioma mediates Akt activation and tumor cell proliferation.Broad targeting of resistance to apoptosis in cancer.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin Anti-cancer Therapies in High Grade Gliomas.Therapeutic targeting of EGFR in malignant gliomas.Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.Current and emerging molecular targets in glioma.Tumor metabolism of malignant gliomas.The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo.Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS/MSn and HPLC-SPE-NMR.Expression level of human miR-34a correlates with glioma grade and prognosis.

P2860

Q21133610-4FAD2C4B-8D18-4E14-BD1C-4950EEA68BE6 Q24618080-B29CFD24-EC2D-46B5-AE4D-4281C20D4BB9 Q26766293-414AFE59-B598-4D9E-94AD-00448184A11B Q26865287-AADF2F7B-162F-4415-8475-7479030CEEE2 Q27490746-4E274092-BC7E-4B31-B18C-4E69A78E70C1 Q28743461-17CA717C-26F3-4729-8514-F657F077C9C4 Q30684049-6062347D-399C-4CA8-A251-8D6C09980B69 Q33764768-1153147E-3FDB-4FC1-8F01-667A49FEB2A1 Q33830769-B37CD27C-AB27-4903-BBE1-AD81062D930E Q33870872-53E64A58-F3CD-4AF5-B1F9-3DDA7DDADAA1 Q33911283-51A958BF-8EE9-4497-A78B-26BFAE0F1E55 Q34218761-3291B016-AF40-4F1D-BB08-CF053514908D Q34226918-75EEB142-A091-4F98-AC25-27380F818F45 Q34688196-5D0780D8-5411-44CE-B3CE-6F72EB58CA50 Q35126108-34197E47-D153-48D4-82BD-EEDC40A0D396 Q35214534-DA227AAC-BC7A-4D30-A2AB-C5AD7FA10585 Q35673598-97037DDB-F730-448B-8156-C06F9F5CFAC4 Q35825491-274C6CDD-4F13-4BAA-9C5C-8EC0D8A9EBBD Q36050424-45093DED-CA3E-4A28-8012-DE432775F8AD Q36307539-0C006898-687F-40AB-B525-62FDEA279588 Q36483749-72620D58-4646-4B30-8F3E-C95E6C507916 Q36497633-0491AC09-FD98-496D-824B-F98A5EFC96D0 Q36943893-B814A7FE-23FF-4F7D-9358-4A071D826B2B Q37290626-4C7C4C20-6A14-4EC7-81D5-7C62246D63AA Q37690755-28049084-7863-4297-ABE6-A45F227B0F33 Q37761935-D3B0C5B0-9EF8-4DA5-B530-A40C2D7D6825 Q37809861-9A5FFD65-B75F-4906-A843-89346A645658 Q38161749-3B51C3C5-B9CF-46BB-89BC-5E6095E635AF Q38740114-641A1AF7-AFDE-4D76-BDBB-ABFFF85D007B Q39500714-6ABB6432-78E6-4C42-9DE8-D13BC8D85150 Q39539196-33321F2A-0547-4C99-8688-7BF1A50B12E2 Q41816118-D66B2371-8097-478D-8502-B5D08DB26A26 Q47106122-69A48EEB-441C-4D18-9464-18B2431B77D6 Q47259620-0DC6D2B2-B767-423C-933A-A64D8B47406B Q47369544-C834BA20-112F-47F4-9D0C-CDA618346443 Q48110181-A9638E92-F889-4F0F-AA98-6EAFA0A3C41A

P2860

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

http://www.wikidata.org/entity/Q37533648

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@en

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@nl

type

label

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@en

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@nl

prefLabel

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@en

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@nl

P1433

Q37533648-4306E596-9A5B-42B7-B704-529BA68B3C05

P1476

Q37533648-0C52D828-DCB4-4B74-B658-EC29AC88F0A7

P2093

Q37533648-0845125B-A1C7-486C-ABBF-DCC28F59514D

Q37533648-712ED865-51C0-4AAD-86B2-B266D910A600

Q37533648-D3DF0713-DBAA-4A8F-BBD2-96C103AA49AD

Q37533648-EB37E4D4-4FD8-449D-8F6E-E7543AC28FD6

P2860

Q37533648-0065A62B-5B46-4BEC-962A-51F910B8E8EB

Q37533648-051E69FA-996A-4351-BB61-BA0886E70587

Q37533648-0AAD0D8D-9632-44A7-8A1D-EF0389859C58

Q37533648-10BCA247-9117-4280-A2F9-00A806B28DF3

Q37533648-117D512B-C206-44E4-AE43-EC79A9CFDF1C

Q37533648-129134F5-81F4-4B92-BB09-41C690E4A45E

Q37533648-14E64690-C03B-40FB-9E9E-A9A9A3A2D109

Q37533648-1789AC23-0FF7-4D0D-ABFC-2140801A4E1B

Q37533648-18705AB0-F980-443F-B4A7-4614E1D6BEE5

Q37533648-1C28A186-5002-4842-8593-64F40667461B

P2888

Q37533648-30FC6078-A130-4923-B97C-078CC0DD9C35

P304

Q37533648-E7123FFB-DC2B-4BD9-AD23-52AF47F241E4

P31

Q37533648-4BBF3ABA-3276-4248-949E-87D50953BEC9

P356

Q37533648-6D871B36-19B2-4019-8FC0-B563F8F3D44D

P433

Q37533648-76E6C1A0-A8EF-4E74-9C47-FC47921AF375

P478

Q37533648-DDC2028C-DFEF-44DF-8CF7-AD69FA6F93EA

P577

Q37533648-E83C852C-0343-4CB6-9ED6-F5A80B243294

P5875

Q37533648-4CA79622-6060-43D5-BB33-C971036B4E1F

P6179

Q37533648-2644D97E-2F98-4814-A929-952D6165D44B

P698

Q37533648-2046BFAC-28AC-40B8-B82B-BE06FB95012B

P921

Q37533648-9DF9855B-B9D3-443E-9A02-2DDCF7CAB531

P932

Q37533648-5716A8BE-A402-4573-A67C-A368BEA2DDC4

P356

J.NURT.2009.04.008

P1433

Neurotherapeutics

P1476

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

@en

P2093

Paul S Mischel

http://www.w3.org/2001/XMLSchema#string

Shawn M Sarkaria

http://www.w3.org/2001/XMLSchema#string

Tiffany T Huang

http://www.w3.org/2001/XMLSchema#string

Timothy F Cloughesy

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

An integrated genomic analysis of human glioblastoma multiforme

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo

P2888

j.nurt.2009.04.008

P304

500-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NURT.2009.04.008

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26324876

http://www.w3.org/2001/XMLSchema#string

P6179

1012911387

http://www.w3.org/2001/XMLSchema#string

P698

19560740

http://www.w3.org/2001/XMLSchema#string

P921

P932

3600166

http://www.w3.org/2001/XMLSchema#string